🟢 Opus Genetics is trading 6.56% up today in pre-market with no clear company-specific catalyst identified

Opus Genetics is trading 6.56% up at $3.90 in pre-market, with no clearly reported August 11, 2026 company-specific catalyst identified.

• August 6: The company issued its second-quarter update.
• August 3: Opus Genetics completed Phase 3 enrollment, with upcoming clinical milestones.
• August 7: RBC reduced its price target while maintaining an Outperform rating; the move was not explicitly linked to the stock move.